We accelerate personalized drug discovery through rapid in vivo drug repurposing. Once we have determined that the cause of the disease is genetic and validated that the causative gene is present in the worms and fishes genomes, our programs enter into three key steps.
In step #1, we rapidly test 4,500 molecules in worms to determine the most promising options for the next step. On average, we typically narrow the molecules down from 4,500 to 10-20 molecules that are the most promising.
Step #1 typically takes 3 – 6 months.
In step #2, we take the 10-20 most promising molecules and test these molecules in fish. We typically narrow the molecules down to 1-2 options that are the most promising to move into the next step.
Step 2 typically takes 6 – 12 months.
In step #3, we take the 1 – 2 most promising molecules and test these molecules in mice. At this phase, we choose the most promising options that is most likely going to be successful in a clinical trial.
Step #3 typically takes 12 – 18 months.
RAPIDLY ADVANCING PROGRAMS
*The ALS Project has been pursued academically by the University of Montreal and the University of Calgary.
INFORMATION FOR FAMILIES
Modelis is patient-centric, and we will guide you each step of the way.
©2020 Modelis inc. All rights reserved